[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522304":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":38,"centralContacts":43,"locations":48,"responsibleParty":66,"collaborators":11,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":11,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":11,"enrollmentInfo":78,"targetDuration":11,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":50,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Hubei Cancer Hospital","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Ondansetron every 3 weeks combined with aprepitant and dexamethasone","EXPERIMENTAL",null,[13,14,15],"Drug: Ondansetron every 3 weeks","Drug: Aprepitant","Drug: Dexamethasone",{"label":17,"type":10,"description":11,"interventionNames":18},"Ondansetron weekly combined with aprepitant and dexamethasone",[14,15,19],"Drug: Ondansetron weekly",[21,26,30,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","Ondansetron every 3 weeks","Ondansetron, Po, 24mg\u002Fd, 3 days' application every 3 weeks",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Aprepitant","aprepitant, Po, 125mg\u002Fd, 1day' application every 3 weeks",[9,17],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"Dexamethasone","dexamethasone, iv, 10mg\u002Fd, 1day' application every 3 weeks",[9,17],{"type":22,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"Ondansetron weekly","Ondansetron, Po, 24mg\u002Fd, 3 days' application weekly",[17],[39],{"name":40,"affiliation":41,"role":42},"Guang Han, MD","Hubei Cancer Hospital, Wuhan, HuBei, China, 430079","PRINCIPAL_INVESTIGATOR",[44],{"name":40,"role":45,"phone":46,"phoneExt":11,"email":47},"CONTACT","13886048178","hg7913@hotmail.com",[49],{"facility":5,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Wuhan","Hubei","430079","China","CN",{"type":57,"coordinates":58},"Point",[59,60],114.26667,30.58333,{"lat":60,"lon":59},[63,65],{"name":64,"role":45,"phone":11,"phoneExt":11,"email":11},"Han Guang, MD",{"name":64,"role":42,"phone":11,"phoneExt":11,"email":11},{"type":42,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"HAN GUANG","Director of the department of Radiotherapy Oncology","100522304","ondanstron-weekly-vs-every-3-weeks-for-prevention-of-nausea-and-vomiting-induced-by-chemotherapy-combined-with-pd-1-blockade-100522304",false,"NCT06080880","Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade","Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade：an Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years, no gender limit;\n2. Pathologically or cytologically confirmed malignant solid tumors;\n3. Scheduled to receive cisplatin-based chemotherapy combined with PD-1 blockade；\n4. TPS \\> 1 %(PD-1);\n5. Adequate hematological function (leucocyte count ≥ 4000\u002FμL \\[to convert to ×109\u002FL,multiply by 0.001\\], hemoglobin ≥ 9.00 g\u002FdL \\[to convert to grams per liter, multiply by 10\\], and platelet count ≥ 100 × 103\u002FμL \\[to convert to ×109\u002FL, multiply by 1\\]);\n6. Hepatic function (alanine aminotransferase and aspartate aminotransferase ≤ 2.0 times the upper limit of the reference ranges), and renal function (creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73 m2 \\[to convert to millimeters per second per meter-squared, multiply by 0.0167\\])；\n7. Estimated survival time \\> 6 months；\n8. ECOG 0-1 points；\n9. Participants being informed and signed written consents.\n\nExclusion Criteria:\n\n1. Nausea or vomiting caused by reasons except for chemotherapy and PD-1 blockade;\n2. Participants with other malignant tumors history previously;\n3. Inability to read, comprehend, and finish questionnaires;\n4. Allergic to the drugs included in this study.\n5. Administered drugs with antiemetic activity within the 24 hours before receiving the first dose of study medication.","ALL","18 Years",{"count":79,"type":80},98,"ESTIMATED","INTERVENTIONAL",[83],"NA","The aim of this randomized study is to compare the efficacy and safety of ondanstron weekly with every 3 weeks for the prevention of nausea and vomiting induced by chemotherapy combined with PD-1 blockade.",[86],"Nausea With Vomiting Chemotherapy-Induced",[88,89,90],"Chemotherapy-induced nausea and vomiting","PD-1 blockade","Ondanstron","2024-02-28",{"date":93,"type":94},"2024-02-29","ACTUAL",{"date":96,"type":94},"2023-12-01",{"date":98,"type":80},"2027-11",{"name":5,"class":6},1]